Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-04 09:27 am Purchase |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Wellington Management Group LLP | 2,694,814 5.240% |
2,694,814 (New Position) |
Filing History |
| 2022-01-31 5:07 pm Purchase |
2022-01-27 | 13D | Kymera Therapeutics, Inc. KYMR |
BIOTECHNOLOGY VALUE FUND L P | 3,586,658 7.000% |
955,996 (+36.34%) |
Filing History |
| 2021-02-16 5:27 pm Purchase |
2020-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 7,948,982 17.900% |
7,948,982 (New Position) |
Filing History |
| 2021-02-16 4:10 pm Purchase |
2020-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Redmile Group LLC | 2,720,489 6.100% |
2,720,489 (New Position) |
Filing History |
| 2021-02-08 10:27 am Purchase |
2021-02-05 | 13G | Kymera Therapeutics, Inc. KYMR |
FMR LLC | 2,442,060 5.492% |
2,442,060 (New Position) |
Filing History |
| 2020-09-03 4:12 pm Purchase |
2020-08-25 | 13D | Kymera Therapeutics, Inc. KYMR |
VERTEX PHARMACEUTICALS INC VRTX |
3,151,121 7.100% |
3,151,121 (New Position) |
Filing History |
| 2020-08-25 5:27 pm Purchase |
2020-08-21 | 13D | Kymera Therapeutics, Inc. KYMR |
BIOTECHNOLOGY VALUE FUND L P | 2,630,662 5.900% |
2,630,662 (New Position) |
Filing History |